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Abstract
Background: Single point mutations at both synonymous and non-synonymous positions within exons can have
severe effects on gene function through disruption of splicing. Predicting these mutations in silico purely from the
genomic sequence is difficult due to an incomplete understanding of the multiple factors that may be responsible.
In addition, little is known about which computational prediction approaches, such as those involving exonic
splicing enhancers and exonic splicing silencers, are most informative.
Results: We assessed the features of single-nucleotide genomic variants verified to cause exon skipping and
compared them to a large set of coding SNPs common in the human population, which are likely to have no
effect on splicing. Our findings implicate a number of features important for their ability to discriminate splice-
affecting variants, including the naturally occurring density of exonic splicing enhancers and exonic splicing
silencers of the exon and intronic environment, extensive changes in the number of predicted exonic splicing
enhancers and exonic splicing silencers, proximity to the splice junctions and evolutionary constraint of the region
surrounding the variant. By extending this approach to additional datasets, we also identified relevant features of
variants that cause increased exon inclusion and ectopic splice site activation.
Conclusions: We identified a number of features that have statistically significant representation among exonic
variants that modulate splicing. These analyses highlight putative mechanisms responsible for splicing outcome
and emphasize the role of features important for exon definition. We developed a web-tool, Skippy, to score
coding variants for these relevant splice-modulating features.
Background
The majority of genes in mammalian genomes are made
up of multiple exons separated by much longer introns.
T oc r e a t eam a t u r em R N A ,e x o n sm u s tb ei d e n t i f i e d
accurately from within the transcript and then spliced
together by removing the intervening introns. This pro-
cess is carried out by a large complex of small nuclear
RNAs and polypeptides known as the spliceosome. Dis-
ruption to the fidelity of splicing, particularly of exons
that are constitutively spliced, can effectively inactivate a
gene by creating unstable mRNAs and defective protein
structure, or cause disease by disrupting the balance of
expression of different splice isoforms [1]. The most
important features for exon recognition are the splice
junctions that define the boundaries of the exons, at
which the spliceosome must assemble. Mutations at
sites causing splicing abnormalities make up around
15% of all point mutations that result in human genetic
d i s e a s e[ 2 ] .H o w e v e r ,t h i sf i g u r ei sl i k e l yt ob eas i g n i f i -
cant underestimate of the contribution of splicing in dis-
ease, as there is an increasing number of studies
showing that mutations within both exons and introns,
but outside of the canonical splice sites, can also disrupt
splicing [3]. In particular, the ability of nonsense, mis-
sense and even synonymous (silent) mutations to cause
exon skipping is often overlooked due to the strong
association of exonic mutations solely with protein cod-
ing changes. Indeed, as the skipping of the exon can
lead to the removal of an entire protein domain or
degradation of the mRNA via nonsense-mediated decay,
splice-affecting variants (including synonymous changes)
are much more deleterious than most missense muta-
tions that substitute a single amino acid. Similarly, exo-
nic variants can also result in deleterious effects by
activating a de novo (that is, not pre-existing) ectopic
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any medium, provided the original work is properly cited.splice site, which is then used in preference to the nat-
ural splice site, shortening the exon. A well-known
example of this is a synonymous mutation in exon 11 of
the human LMNA gene that creates a 5’ ectopic splice
site. This shortens the protein sequence through frame-
shift, and causes the rare premature aging disorder
Hutchinson-Gilford progeria [4].
The mechanism by which these internal exonic muta-
tions exert their effect is still not fully understood, but
they are most commonly associated with changes in reg-
ulatory elements within the exon that are important for
exon definition. The spliceosome must distinguish genu-
ine splice sites from a collection of sequences in the
intron that resemble them but are never used (known as
pseudo splice-sites). Therefore, correct exon recognition
requires additional auxiliary signals present both within
the exon and in the introns, as canonical splice sites are
n o ts u f f i c i e n tt od e f i n et h eproper splice sites. These
regulatory sequences, important in both constitutive and
alternative splicing, can beb r o a d l yd e f i n e db yt h e i r
intergenic location and their effects on splicing. Those
located within the exon and promoting exon inclusion
are referred to as exonic splicing enhancers (ESEs) and
those inhibiting exon inclusion are referred to as exonic
splicing silencers (ESSs). Similarly those located in the
intron are referred to as intronic splicing enhancers and
intronic splicing silencers, although these are more com-
monly associated with specifying alternative splicing [5]
or splicing of non-canonical introns [6].
Although identification and characterization of the
complement of proteins that bind specific exonic enhan-
cer and silencer elements is far from complete, most
enhancer sequences within exons have been found to
bind members of the serine/arginine-rich (SR) protein
family, while many silencing elements are bound by
members of the heterogeneous ribonuclearprotein
(hnRNP) family [7]. ESE-bound SR proteins promote
exon definition by directly recruiting and stabilizing the
splicing machinery through protein-protein interactions
[8] and/or antagonizing the function of nearby silencer
elements [9]. Silencers are not as well characterized as
enhancers, but ESS-bound hnRNPs are thought to med-
iate silencing through direct antagonism of the splicing
machinery or by direct competition for overlapping
enhancer-binding sites. The intrinsic strength by which
the splice sites are recognized by the spliceosome as
well as the antagonistic dynamics of proteins binding
ESEs and ESSs control much of exon recognition and
alternative splicing. It is therefore not surprising that
exonic splicing regulatory sequences (ESRs) are now
increasingly recognized as a major target and a common
mechanism for disease-causing mutations leading to
exon skipping in functionally diverse genes. Examples of
disease mutations reported to destroy ESE motifs and
cause exon skipping include those in the BRCA1 [10],
SMN1/2 [11], PDHA1 [12] and GH [13] genes.
Given the critical role of these sequences in exon spli-
cing, significant research efforts are focused on identify-
ing the complement of ESE and ESS binding sites
involved in constitutive splicing. The assortment of
enhancer and silencer sequences recognized by known
s p l i c i n gf a c t o r si sc o n s i d e r a b l e[ 3 ] .T h i ss u g g e s t st h a t
ESRs may represent numerous functionally distinct
classes, or may be recognized in a degenerate fashion.
This ‘fuzzy’ definition of ESRs has meant that their pre-
cise characterization has proved challenging. A large
group of existing ESE/ESS datasets has been identified
either experimentally [14,15] or through the use of com-
putational approaches followed by some form of experi-
mental verification of a subset of predictions [16-19]
(for an overview see Table 1 and [20]). The motifs
defined in each dataset are commonly represented as
hexamers or octomers, or encoded as position weight
matrices analogous to transcription factor binding sites.
Motifs predicted by these approaches are partially over-
lapping, but also yield certain proportions that are
unique or even contradictory. Recent studies have also
suggested that both global and local RNA secondary
structure may also play a role in the recognition and
activity of splicing regulatory motifs in certain cases
[21,22]. Despite our access to these varied splicing regu-
latory datasets, the question of whether they are effec-
tive in detecting the appropriate splicing regulatory
changes associated with splice modulating variants has
yet to be systematically assessed.
The development of high throughput sequencing tech-
nologies provides an unprecedented opportunity to
identify disease alleles associated with both common
and rare disorders. In the likelihood that exonic splice-
affecting mutations are a commonly overlooked phe-
nomena in disease and transcript variation, it is impor-
tant to identify the genomic features most relevant in
characterizing novel splice-affecting genome variants
(SAVs). We performed a comparative analysis using sets
of experimentally verified SAVs against SNPs common
in the human population, the majority of which are
likely to be splicing-neutral. Comparative analysis of
SNP datasets is a powerful approach to highlight charac-
teristics that define disruptive sequence variants. A simi-
lar approach has been employed previously to predict
SNPs affecting transcriptional cis-regulation [23] as well
as to measure selective pressure on genomic elements
such as conserved non-coding sequences [24] and spli-
cing enhancers [25]. Here, we focused our main analyses
on the most prevalent and least characterized SAVs,
those that cause exon skipping, using a battery of bioin-
formatics approaches as well as a systematic comparison
of all currently available ESE/ESS datasets, to identify
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environment that are most likely to be predictive for
exon skipping events. Extending this analysis, we also
identified relevant features associated with SAVs causing
increased exon inclusion and ectopic splice site creation.
Combined, these features are useful to predict the prob-
ability of novel splice-modulatory events and are made
available through a web server.
Results
To identify features associated with exon skipping SAVs,
we collated a set of experimentally verified variants in the
human genome that independently cause exon skipping
from extensive literature searches and the Alternative
Splicing Mutation Database [26]. We excluded all var-
iants from this list that may affect splicing through other
well-defined mechanisms, such as nonsense-mediated
exon skipping or disruption of canonical splice sites (see
Materials and methods). A total of 87 variants were iden-
tified (currently the largest dataset of its kind), and their
genomic positions mapped back onto the human genome
(hg18). As the majority of analyses in this paper involve
exon-skipping SAVs, we refer to these variants simply as
‘SAVs’, unless otherwise indicated. This set is made up of
32 synonymous and 55 missense SAVs distributed across
43 genes and 47 individual exons (Additional file 1). Of
these, 87% (41) were constitutively spliced and 13% (6)
were alternatively spliced cassette exons.
In addition to known SAVs, a set of spicing-neutral
variants (that is, that have little or no effect on exon
splicing) served as a standard for comparison.
Although no large-scale set of experimentally verified
splice-neutral variants has been published, through lit-
erature searches we identified a set of 80 variants that
were tested in mini-gene splicing assays and were
found to have no effect on splicing (Additional file 2).
Unfortunately, around half of these derive from artifi-
cial mutagenesis studies, and may therefore include
certain artificial biases. As an alternative, since exon-
skipping events are likely to be largely deleterious, we
exploited the principle that SAVs will be largely absent
from polymorphisms common in the human popula-
tion. Phase II HapMap SNPs represent both a high
quality and extensive genome-wide set of human poly-
morphisms, as they have been genotyped for 270 indi-
viduals in four populations [27]. From this set of 3.1
million SNPs, we took all SNPs that fell in internal
(that is, spliced) coding exons that were polymorphic
in at least one individual and filtered them in the same
way as SAVs (see Materials and methods). In addition,
we only retained SNPs where we could determine the
ancestral and derived allele with high confidence by
utilizing orthologous positions in the chimp and maca-
que genomes. This approach allowed us to make an
assumption of the allele directionality, which was
important for detecting loss or gain of splice regulatory
elements. The resulting dataset contained 15,547 SNPs
with roughly equal numbers of synonymous and mis-
sense alleles (7,922 and 7,625, respectively). These
SNPs fell within 13,163 individual exons from 7,038
genes. For ease of reference, we refer to this set of
HapMap SNPs as ‘hSNPs’.
Using these sets of variants, we carried out compara-
tive analyses to identify the features that discriminate
Table 1 Exonic splicing regulatory elements datasets used in this study
ESR
dataset
Format Method Reference
ESEFinder 4 ESE PWMs Set of four experimentally derived ESE binding site matrices for four SR proteins (SF2, SC35, SRp40,
SRp55) identified by an in vitro SELEX approach with specific SR protein complementation
[14]
Fas- (hex3)
ESS
176 ESS hexamers Set of experimentally derived ESSs identified in vivo through cloning of random decamers into
fluorescence activated minigene reporter by selecting those sequences that cause exon skipping.
Unique candidates were clustered and represented by non-degenerate hexamers
[15]
RESCUE-
ESE
238 ESE hexamers Set of putative ESEs derived from overrepresented hexamer motifs in exons versus introns and exons
with weak splice sites versus exons with strong splice sites
[17]
PESX 2,096 ESE/974 ESS
octomers
Set of putative ESEs (PESE) and ESSs (PESS) overrepresented and underrepresented in internal non-
coding exons versus unspliced pseudoexons and 5’ UTRs of intronless genes
[18]
NI-ESR 979 ESE/496 ESS
hexamers
Uses the neighborhood inference (NI) algorithm to identify new candidate ESEs and ESSs using a set
of previously identified ESEs/ESSs. The NI algorithm searches the sequence neighborhood of a
particular hexamer and scores it by whether the surrounding sequences contain mostly known ESEs,
ESSs or neither. Predicted candidates were verified by cross-validation and a subset was
experimentally validated
[19]
Ast-ESR 285 hexamers Motifs based on computational analysis of overrepresented and conserved dicodons in orthologous
human-mouse exons. Putative ESRs are not labeled as ESEs or ESSs as a number were found to act as
both enhancers and silencers in minigene assays depending on sequence context.
[16]
Composite-
ESR
400 ESE/217 ESS
hexamers
Combined set of ESE/ESS based on RESCUE-ESE, PESE, PESS and Fas-ESS datasets [60]
PWM, position weight matrix.
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sequence level (such as changes in the underlying spli-
cing regulatory sequences and physical location within
exons), or at the exon level (to predispose an exon to
exon-skipping events) to ena b l eap r e d i c t i v ef r a m e w o r k
for uncharacterized variants.
Variant-based features
Changes in exonic splicing regulatory sequences
Our systematic assessment of all seven currently avail-
able ESR datasets examined their ability to identify
splice-regulatory elements in the verified SAV
sequences. This approach assessed the types of motif-
altering changes associated with SAVs and provided
benchmarking of the seven ESR collections (Table 1) to
determine which most strongly differentiated real splice-
affecting variants from common polymorphisms. Of
these seven sets, two contain ESEs (ESEFinder and RES-
CUE-ESE), one represents ESSs (Fas-ESS) and the
remaining four sets contain both ESEs and ESSs (PESX,
NI-ESR, Ast-ESR and Composite-ESR). For both SAV
and hSNP sequences we measured three possible types
of changes in the ancestral versus derived allele (or wild
type versus disease allele) as a result of the variant: ESR
loss, ESR gain and ESR alteration (see Materials and
methods).
We first examined whether the proportion of SAVs
with a particular type of ESR change was significantly
different from that of hSNPs. Our comparative analyses
identified two significant changes associated with var-
iants that cause exon skipping: the gain of sequences
defined as ESSs and the loss of sequences defined as
ESEs (Figure 1; Additional file 3). Of these, we found
that ESS gains had stronger discriminatory power than
ESE losses. All the ESS datasets identified a significantly
greater proportion of SAVs causing gains of ESSs. In
contrast, results for ESE losses were split. NI-ESE, RES-
CUE-ESE and Comp-ESE showed a moderate but
Figure 1 Proportion of variants with gains or losses in exonic splicing regulatory sequence with significant differences between
splice-affecting genome variants and HapMap SNPs. SAVs were characterized by (a) the loss of ESEs and (b) the gain of ESSs. As a
comparison, ESEfinder, Ast-ESR and PESE losses are also included. These were not significantly different between SAVs and hSNPs. Z score P-
values from random bootstrap sampling relating to each type of change are located on the right of the histogram.
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than hSNPs. Losses of ESEfinder motifs were roughly
equal between SAVs and hSNPs, both as a group of
motifs and individually (Figure 1; Additional file 3).
Nevertheless, we hypothesized that because the thresh-
old set for each ESEFinder binding site is somewhat
arbitrary, single base changes that cause a binding site
to be ‘lost’ may not be functionally equivalent and that
changes in certain positions may be less tolerated than
others. We found one position in each binding matrix
that occurred at significantly higher numbers in SAVs
compared to hSNPs (by c
2 test, P < 0.05; Additional file
4). Hence, there may be different functional constraints
acting along the binding sites that are not properly cap-
tured by the default scoring thresholds and the position
weight matrix scores as currently employed. Ast-ESRs,
while not explicitly defined as ESEs or ESSs, showed no
significant difference between variant groups for losses,
alterations or gains [16]. Consistent with the direction
of the previous ESR changes, SAVs were also signifi-
cantly diminished for gains of ESEs using the NI-ESE
dataset (Figure 1; Additional file 3).
The extent of ESR changes further differentiates SAVs from
hSNPs
We investigated whether SAVs are further distinguished
by the cumulative extent of the ESE losses and ESS
gains. Many of the sets of putative ESRs are represented
as hexamers (for example, RESCUE-ESE, NI-ESRs,
PESXs, and so on), either because this is often the size
of a single protein-binding site (for example, the GAA-
GAA ESE [28]), or because they are a reduced represen-
tation of larger binding sites. Because point variants may
modulate several overlapping binding sites simulta-
neously, those affecting larger numbers of predicted
sites are more likely to have significant impact, for
which we assessed predictive power. The results showed
that in all ESR sets except ESEfinder, numbers of ESS
gains and ESE losses were much greater in SAVs than
hSNPs (Additional file 3). We saw the greatest separa-
tion from hSNPs using NI-ESSs gains (98 gains in SAVs
versus a mean of 32 in hSNPs, Z-score P = 1.92 × 10
-17)
and NI-ESEs losses (138 losses in SAVs versus a mean
of 69 in hSNPs, Z-score P =2 . 6 8×1 0
-10), although
RESCUE-ESE, Fas-ESS and Composite-ESR also give
good, strongly statistically significant separations, despite
the much smaller size of these datasets compared to NI-
ESRs (Table 1).
For NI-ESR, losses or gains of two or more motifs were
prevalent, with the divergence between SAVs and hSNPs
becoming larger as the total number of occurrences
increased (Figure 2a, b). When the extent of ESS gains and
ESE losses were combined as a total number of changes,
46% of SAVs had four or more such changes compared to
only 9% for hSNPs (Figure 2c). Furthermore, we compared
the set of 80 experimentally verified splice-neutral variants
against the hSNP dataset and found that no category of
ESR change was significantly different (Additional file 3).
This supports our assumption that hSNPs act as an appro-
priate proxy for splice-neutral variants and confirms that
significant ESR differences are detectable between splice-
affecting and splicing-neutral datasets.
Finally, using a recently established computational
method [22], we investigated whether taking local RNA
secondary structure into consideration improved the
ability to distinguish functionally relevant ESR changes
in SAVs from those in hSNPs. We found little evidence
that local RNA secondary structure, as implemented by
this method, improved our ability to differentiate these
two datasets further (see Additional file 5 for methods
and results).
Splice-altering sequence changes are under negative
selection in common SNPs
In the previous comparative analyses, we assumed that
the differential signal in ESR changes between SAVs and
hSNPs was a composite consequence of both functional
ESR changes in SAVs and selective pressure to avoid
those changes in common hSNPs [25]. To test this
assumption, we investigated whether the proportion of
each type of ESR change in SAVs and hSNPs, using the
NI-ESR dataset, would differ when compared to an
‘expected’ neutral distribution created through permuta-
tion (see Materials and methods). This permuted distri-
bution represents what we would expect if variants
occurred randomly under no selective pressure for spli-
cing. We found that while hSNPs followed the expected
distribution closely for many of the changes, SAVs had
almost two-fold higher proportions of ESS gains and ESE
losses (Figure 3), confirming that these types of changes
were a non-random, characteristic property of SAVs.
Moreover, the highly significant difference in ESS gains
between SAVs and hSNPs can be further explained by a
significant reduction for this type of change in hSNPs
compared to the expected distribution (5.6% of changes
i nh S N P sv e r s u s8 . 3 %u n d e rn e u t r a l i t y ,c
2 test P =1 . 7×
10
-8), suggesting negative selection against the gain of
silencers in common variants. We also identified a five-
fold increase in the proportion of variants that cause
direct changes from an ESE to an ESS in SAVs compared
to both the expected and hSNP distributions (4.1% of
changes in SAVs versus 0.8% under neutrality/hSNPs, c
2
test P =3 . 8×1 0
-12; Figure 3), indicating that this type of
change represents a strong indicator of splice-affecting
changes.
Significant ESR changes in variants that increase exon
inclusion
We carried out the same comparative analysis against
hSNPs using a smaller set of 20 exonic variants that
have been experimentally verified to cause increased
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Page 5 of 23Figure 2 Splice-affecting genome variants are characterized by losses of large numbers of NI-ESEs and the gain of large numbers of
NI-ESSs, often in combination. For both ESE losses and ESS gains, the proportion of SAVs with changes of two or more were significantly
greater compared to hSNPs. Combinations of ESE losses and ESS gains, as opposed to each occurring independently, are highly enriched in
SAVs compared to hSNPs (bottom graph).
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some of the statistical power of the larger exon skip-
ping SAV set, we found that these variants were signif-
icantly enriched for ESSs losses (21 losses versus a
mean of 5 in hSNPs, empirical P =1×1 0
-4; Additional
file 3). They also exhibited greater numbers of ESE
g a i n s( 2 5g a i n sv e r s u sam e a no f1 5i nh S N P s ,e m p i r i -
cal P = 0.034) and lower numbers of ESE losses (5
losses versus a mean of 16 in hSNPs, empirical P =
0 . 0 0 9 7 ) .T h e s ec h a n g e sw e r et h eo p p o s i t eo ft h e
changes caused by skipping SAVs and consistent with
regulatory changes expected to increase exon defini-
tion. These results highlighted the antagonistic inter-
play between ESEs and ESSs in stabilizing or
destabilizing exonic splicing.
Proximity to exon boundaries
Previous studies have shown that a number of exonic
characteristics are affected by proximity to the exon
junction, including ESE density [25], evolutionary con-
straint [16,29] and codon bias [30]. Although
circumstantial, this evidence supports the view that the
boundaries of exons contain regulatory ‘hotspots’ that
m a yb em o r ec r i t i c a lt os p l i c i n gt h a nc e n t r a l i z e d
regions. To investigate whether SAVs are more likely to
be disruptive if located preferentially in these hotspot
regions, we divided all SAV exons and HapMap exons
into six equal parts and binned the SAV or hSNP var-
iants according to their locations. Figure 4 shows that
hSNPs were distributed roughly equally across the
exons, with a small depletion at exon boundaries,
w h e r e a sS A V sw e r ee n r i c h e dc l o s et ot h ee x o nb o u n d -
aries and depleted towards the center (46% of SAVs
located at the peripheral sections of exons versus 28.5%
of hSNPs, P = 0.005). Nevertheless, over a quarter of
the SAVs are located within the central sections of the
exon, suggesting that while variants located at the per-
ipheries of the exon are likely to have the greatest effect
on splicing, other elements important for splicing may
be found at positions across the exon, but not with dis-
criminatory power for this analysis.
Figure 3 Distribution of specific types of NI-ESR changes for SAVs and hSNPs compared to neutral expectation. The tilde symbol (~)
signifies an alteration where the hexamer is designated an ESE, neutral or ESS in both the wild-type and variant sequences. The arrow
represents the direction of the change as a consequence of the change between wild type and variant hexamer. The neutral expected
distribution reflects the underlying probability of each type of change given the ESE/ESS distribution among NI hexamers and the genome-wide
nucleotide substitution bias in coding regions.
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The availability of multiple sequenced mammalian gen-
omes provides the opportunity for evolutionary compar-
isons of functional constraint across related species.
Splicing patterns and exonic splicing regulatory ele-
ments are generally conserved across mammals [31].
Therefore, sequences important for splicing should be
detectable by greater evolutionary sequence conserva-
tion; a case that is proven for intronic factors [32]. We
hypothesized that the regions surrounding SAVs should
be under greater evolutionary constraint than regions
surrounding neutral variants. However, within coding
exons, the constraint on the sequence due to splicing
has to be decoupled from pre-existing protein-coding
constraint. One solution is to measure conservation at
synonymous codon positions, which are normally con-
sidered to be neutrally evolving. Several studies have
demonstrated that ESRs increase selective constraint on
synonymous positions [16,33]. An extreme example is
the ultra-conservation of coding sequences that are
associated with auto-regulatory alternative splicing of
‘poison exons’ in SR proteins [34].
To score regulatory constraint in coding regions, we
created an expectation-based scoring matrix for each of
the 192 positions of the genetic code. The scores were
inversely proportional to conservation levels in genome-
wide human/mouse/rat/dog DNA multiple alignments
(see Materials and methods). By using a scoring scheme
based on real evolutionary data, the scoring matrix not
only preferentially scores synonymous over non-synon-
ymous positions, but also incorporates other influences,
such as codon bias and hypermutability. For example,
the highest scores in the matrix are at synonymous posi-
tions in hypermutable CpGs (that is, TCG, ACG, CCG
and GCG) as these are the least conserved coding posi-
tions genome-wide (Figure 5a). Using this scoring
matrix, we calculated regulato r yc o n s t r a i n t( R C )s c o r e s
in localized coding regions, representing all possible
hexamer positions surrounding a variant, for all SAVs
and hSNPs (Figure 5b) and compared the mean RC
scores of all non-overlapping regions for each set.
Results showed that sequences containing SAVs had sig-
nificantly higher mean conservation scores than a ran-
dom sampled distribution of hSNPs (1.583 versus a
Figure 4 SAVs are enriched at the borders of exons. SAV and hSNP containing exons were divided into six equal sections and the
proportion of variants falling into each section was plotted. While hSNPs were roughly distributed equally across the exon (with some depletion
towards the edges), SAVs are significantly enriched at both edges of the exon (P = 0.005).
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-9; Figure
5c, orange distribution).
We addressed a variety of sources of bias that could
confound the outcome of the conservation analysis. For
example, rates of synonymous and non-synonymous
substitutions decrease close to splice junctions [29,30].
Data from hSNPs confirmed this result by showing that
the RC scores were negatively correlated with distance
from the splice junction (Additional file 7). However,
since SAVs are enriched close to splice junctions, we
repeated the analysis choosing hSNPs with similar dis-
tances from the splice junction as those in the SAV set.
This shifted the hSNP distribution to greater mean RC
scores (Figure 5c, blue distribution), but the difference
with SAVs remained highly significant (1.583 versus a
mean of 1.266 in hSNPs, Z score P = 1.92 × 10
-8).
Figure 5 Regions surrounding SAVs are under greater non-coding evolutionary constraint. (a) We created a 192-codon position-specific
scoring matrix based on genome-wide conservation levels across mammals. Matrix scores are visualized increasing from green to red. As scores
are inversely proportional to the genome-wide conservation of each codon position, conservation levels can also be visualized using the same
matrix, decreasing from green to red. (b) For each variant, four-way mammalian multiple DNA alignments were extracted for a region
surrounding the variant, and a score assigned to each fully conserved column via the scoring matrix, and the total normalized by the length of
the alignment. An example of a random synonymous CgG variant is shown. (c) The mean conservation score for all SAVs (blue arrow) and SAVs
on autosomes (yellow arrow) was compared to a distribution of randomly sampled sets of scores from all hSNPs (orange distribution). Randomly
sampled distributions of hSNPs were also created controlling for minimum distance from a splice junction by having similar distributions in this
regard as SAVs (blue distribution). A distribution of mean conservation scores was also produced for hSNPs from autosomes also controlled by
minimum distance from the splice site (yellow distribution).
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to SAVs on the X chromosome contributing 35% of the
variant set, compared to just 1.38% of the hSNP set.
Prior SNP analyses identified the X chromosome as hav-
ing lower rates of heterozygosity than autosomes [27],
and human-mouse comparisons showed that genes on
this chromosome were under greater evolutionary selec-
tion [35]. It was possible, therefore, that the prevalence
of SAVs from the X chromosome contributed to the sig-
nificantly higher conservation scores. We found that
mean RC scores for hSNPs on the X chromosome were
significantly higher than for other chromosomes (1.34
versus 1.24, Kolmogorov-Smirnov (K-S) test P = 0.008).
Similarly, SAVs on the X chromosome had a higher
mean RC score than SAVs on other chromosomes but
the difference was not statistically significant (1.57 ver-
sus 1.67, K-S test P = 0.33) due to small sample sizes.
We therefore repeated the analysis using only SAVs and
hSNPs on autosomes (also controlling for distance from
the splice junction; Figure 5c, yellow distribution). The
difference in mean RC scores was further decreased but
nevertheless remained highly significant (1.55 versus
1.25, Z score P =1 . 2 8×1 0
-5). Therefore, the predomi-
nance of SAVs from the X chromosome was not suffi-
cient to explain the greater regulatory constraint
surrounding SAVs.
We also examined whether SAV exons were more
highly conserved than HapMap exons. We compared
percent-identity from four-way multiple alignments,
across entire exons or within non-synonymous positions
of exons, excluding the X chromosome. No significant
differences were found in mean percent-identities in
non-synonymous positions (89% in SAV exons versus
88.7% in hSNP exons, Z score P =0 . 1 2 2 )o ro v e r a l l
(77% in SAV exons versus 75% in hSNP exons, Z score
P = 0.063). Furthermore, similar results were obtained
using HapMap exons of all sizes, or those that closely
resembled the size distribution of SAV exons. By con-
trolling for alternative sources of constraint we con-
cluded SAVs occur in regions of exons that are under
greater non-coding constraint, indicative of negative
selection for important function.
Exonic environment
We addressed features associated with exon definition to
test whether exons containing SAVs (which we will term
‘SAV exons’) are significantly different in these aspects
from exons containing hSNPs (termed ‘HapMap exons’)
or from exons in general, indicative of a pre-existing
weakness or predisposition to the effects of SAVs.
Exon size
Ac o m p a r i s o no fe x o nl e n g t h sb e t w e e nS A Va n dH a p -
Map exons showed that SAV exons were significantly
smaller (mean = 125.1 bp versus 197.8 bp, K-S test P =
1.269 × 10
-7). However, further comparison of the SAV
exons to internal exons from the Hollywood exon anno-
tation database [36] showed that both the mean (125 bp
versus 136 bp, P = 0.39) and median (112 bp versus 120
bp, P = 0.051) values of the SAV exons, although lower,
were not statistically different in a randomized bootstrap
analysis (see Materials and methods). When compared
directly to constitutive Hollywood exons, HapMap
exons were significantly larger (K-S test P < 2.2 × 10
-16).
We examined the potentially confounding problem of
larger HapMap exons through simulation analyses and
showed that the probability of an exon containing a
SNP increased as exon length increased (see Materials
and methods). The simulated exons with SNPs had the
same length distribution as HapMap exons (Additional
file 8). We therefore controlled for equivalent exon size
in all subsequent analyses.
Splice site strengths
Signals critical for exon definition are the 5’ and 3’
splice sites and branch point. The strength of these sig-
nals may influence whether an exon is constitutively or
alternatively spliced, creating conditional dependency on
ESEs and vulnerability to their loss. We found that the
mean 5’ and 3’ splice site scores were lower in SAV
exons than HapMap exons but were not statistically sig-
nificant (Table 2). Assessing exons with large numbers
(≥ 2) of NI-ESEs losses and/or NI-ESS gains revealed
stronger 3’ splice site scores in HapMap exons than
SAV exons (Table 2), suggesting stronger 3’ splice sites
m a ys h i e l ds o m eH a p M a pe x o n sf r o mt h ee f f e c t so f
ESR-changing SNPs. Nevertheless, the large overlap in
splice site strengths between these two groups indicated
that splice site strength could not be used to uniquely
predict SAV vulnerability in exons.
ESR density in exons and introns
A major feature postulated to distinguish exons from
introns is higher densities of ESEs and low or absent
densities of ESSs. The exact opposite is true of introns
and pseudoexons. We therefore looked at the density of
exonic splicing regulators in SAV and HapMap exons
using the NI-ESRs. We found that SAV exons have sig-
nificantly lower densities of ESEs and higher densities of
ESSs across the exon length (Table 2 and Figure 6). To
confirm that these were features specific to SAV exons
rather than something particular to HapMap exons, we
repeated the comparison to random genome-wide exons
and found very similar results, suggesting that this is a
feature characteristic of SAV exons. ESR densities of
SAV exons are, in many cases, more comparable to an
intronic environment represented in flanking introns
(mean ESE density = 0.26, mean ESS density = 0.2; see
Materials and methods). Moreover, directly flanking
SAV exons, we found that intronic sequences showed
higher densities of ESSs and slightly lower densities of
ESEs than around hSNP exons (Table 2).
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Page 10 of 23Variants that activate de novo ectopic splice sites
Next, we assessed features that define exonic variants
that create de novo ectopic splice sites. We used a set of
54 experimentally verified examples of de novo ectopic
splice site variants (Additional file 9) to discern features
that distinguish our two sets of SAVs (that is, ‘ectopic
SAVs’ and ‘skipping SAVs’) from each other and from
hSNPs. First, to measure splice site creation, we used a
simple metric, ΔSS, to measure the maximum difference
in splice site scores between these two sequences for all
possible 5’ and 3’ splice sites around the variants (see
Materials and methods). A large positive delta score
suggests a change in the surrounding sequence towards
a better scoring splice site. Requiring a relatively low
ΔSS score of at least 1 captured the majority of ectopic
SAVs (approximately 85%) compared to 20% of skipping
SAVs and 8% of hSNPs. We also compared the highest-
scoring variant-generated splice site to the natural splice
site score. Over half of ectopic SAVs created ectopic
splice sites that were comparable to or stronger than the
natural splice site, in contrast to a tiny proportion of
skipping SAVs and hSNPs (Figure 7a). Thus, these two
metrics represent excellent features to discriminate ecto-
pic SAVs from splicing SAVs. In support of this conclu-
sion, one of the two exon skipping SAVs we predicted
to also create strong ectopic splice sites, a synonymous
mutation in the ATR gene, has been shown
experimentally to cause a combination of both exon
skipping and ectopic 5’ splice site activation [37].
An additional feature of ectopic SAVs was a highly sig-
nificant excess of ESS gains (P =2 . 8 5×1 0
-15)a n dE S S
alterations (P = 1.95 × 10
-3) compared to hSNPs, similar
to that seen in skipping SAVs. The degree of ESS gains
in ectopic SAVs was even greater than that for skipping
SAVs, averaging 1.28 ESS gains per variant compared to
1.12 for skipping SAVs and 0.39 in hSNPs. When aver-
aged across all internal constitutive exons, we found NI-
ESS density spiked near splice junctions (Figure 7b),
which was consistent with previous studies on smaller
ESS datasets [15,38], suggesting a possible explanation
for the excess in ESS gains. To address this further, we
compared the ectopic SAVs to a set of 54 hSNPs that
were tightly scored as ‘ectopic-like’ (but showed no evi-
dence of splice site creation in mRNA or EST datasets;
see Materials and methods). We found that ectopic
SAVs had almost a 2.5-fold greater number of ESS gains
(68 versus 28) and a 1.8-fold greater number of ESS
alterations (23 versus 13), despite both sets having simi-
lar distributions of maximum ectopic splice site scores
(KS-test P = 0.11). The process of creating strongly
scoring splice-site consensus sequences could not, there-
fore, fully explain the enrichment in ESS changes in
SAVs. Additional ESS creation may facilitate activation
of the new ectopic splice sites by inhibiting the natural
Table 2 Significance of exon and intron-related features for skipping SAV and HapMap exons
Exon feature SAV mean hSNP sampled mean Z-score P-value
Exon splice junction strength
Exon 3’ SS score (all exons) 7.811 8.489 -1.90 0.057
Exon 5’ SS score (all exons) 7.885 8.302 -1.43 0.154
Exon 3’ SS score (with ESR) 7.568 8.534 -2.03 0.022
Exon 5’ SS score (with ESR) 8.008 8.371 -1.71 0.230
Exon ESR density
ESEfinder density FL 0.126 0.152 -3.78 1.53 × 10
-4
NI-ESE density FL 0.323 0.372 -3.37 7.37 × 10
-4
NI-ESS density FL 0.133 0.093 4.30 1.67 × 10
-5
ESEfinder density W40 0.129 0.153 -3.15 0.0016
NI-ESE density W40 0.324 0.379 -3.47 5.18 × 10
-4
NI-ESS density W40 0.140 0.094 4.50 6.85 × 10
-6
Intronic ESR densities
Upstream NI-ESE density 0.201 0.224 -1.55 0.122
Downstream NI-ESE density 0.235 0.250 -1.06 0.314
Upstream NI-ESS density 0.295 0.241 2.44 0.014
Downstream NI-ESS density 0.258 0.210 2.36 0.018
For each feature, the mean values for non-redundant SAV exons were compared to a bootstrap distribution of sampled means for HapMap exons of similar sizes
(hSNP sampled mean). For exon splice junction strength, results marked ‘all exons’ indicate that the comparison was done using all exons in both datasets and
those marked ‘with ESR’ indicate comparisons using only exons containing a variant with splice-associated ESR changes, that is, ESE loss and/or ESS gain. For
exon ESR densities, densities were either measured across the full length of the exon (FL) or in windows of 40 bp at either side of the exon (W40). For exons <80
bp in length, the W40 density is the same as full length density to avoid redundancy. Intronic ESR densities were measured in the first 100 bp upstream and
downstream of the exon. SS, splice site.
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Wang et al. [38] whereby ESS motifs placed between
competing 5’ and 3’ splice sites consistently inhibited
the use of the intron-proximal splice site.
Finally, the location of ectopic SAVs and ‘ectopic-like’
hSNPs across exons revealed very different distributions
(Figure 7c). Ectopic SAVs were predominantly located
in the half of the exon closest to the natural splice site
they replaced. The reverse was true of ‘ectopic-like’
hSNPs, which were distributed across the exon in an
opposite manner. These differences, in addition to the
lack of silencer gains, likely account for the lack of activ-
ity of these ‘ectopic-like’ hSNPs.
Skippy - a web tool for the detection of splice-modulating
exonic variants
It is important for researchers screening for causative
variants associated with disease to have access to user-
friendly bioinformatics tools that can score variants for
relevant splice-associated features. In this way, variants
can be either prioritized for further splicing-based func-
tional assays or the results can be used to further eluci-
date the mechanism of aberrant splicing when a causal
variant has been implicated. To this end, we developed
a publicly accessible web-based tool, Skippy, to allow
users to rapidly score human exonic variants for all rele-
vant exon-skipping features identified in this study. As
well as these features, Skippy can also be used to iden-
tify potential ectopic SAVs.
Unlike other splicing assessment tools that require
laborious extraction of the exonic/intronic sequence for
input and only allow a single sequence to be submitted
at a time (for example, [22,39]), Skippy requires only the
chromosomal location and identity of the variant alleles
as input, accepting up to 200 variants at a time. Results
are returned in HTML tabular form as well as a tab-
delimited text file. To facilitate interpretation of results,
Figure 6 Exons containing SAVs have significantly lower ESE and significantly higher ESS densities than exons containing hSNPs.A sa n
illustration, the proportion of overlapping hexamers that are considered ESEs (green), ESSs (red) or splice neutral (grey) was plotted for 35 exons
containing SAVs (that cause ESE/ESS changes) and a set of 35 randomly selected, length-matched hSNP-containing exons. Exons in both sets are
sorted in descending order by ESS density.
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hSNPs from similar genomic contexts. For example, the
RC score for a candidate variant can be compared to a
distribution of RC scores for hSNPs having similar fea-
tures, such as equivalent minimum distances from the
splice junctions. The web tool is freely available at [40].
Discussion
The emergence in recent years of high throughput geno-
typing and resequencing technologies provides an
unprecedented opportunity to identify disease alleles
associated with both common and rare disorders. As
functional characterization is highly laborious and time
consuming, computational prioritization is a preferred
approach to assessing disease candidates. Exonic muta-
tions are traditionally assessed for an effect on protein
function; however, those that are translationally silent
are often overlooked for roles in exon skipping and
ectopic splice site creation. Moreover, variants are
traditionally only considered in the vicinity of splice
sites if they fall directly at splice boundaries, whereas we
have shown that SAVs are enriched in regions near, but
not at, the splice junctions. Any of these seemingly
innocuous sequence changes may have greater conse-
quences for gene function than a single missense muta-
tion. We therefore showed that SAVs have novel
features distinguishing them from common human poly-
morphisms through a succession of bioinformatics
approaches and built a novel web tool for examining
genomic sequence changes that are likely to affect
splicing.
Exon skipping SAVs cause local changes in splice
regulatory elements
Our comparative analyses identify two main types of ESR
changes associated with exon skipping: the gain of
sequences defined as ESSs and the loss of sequences
d e f i n e da sE S E s .W ea r et h ef i r s tt or e p o r tt h a ta l lE S S
Figure 7 Features that characterize variants that activate de novo ectopic splice sites (’ectopic SAVs’). (a) Most ectopic SAVs, in contrast
to hSNPs and skipping SAVs, have a large ΔSS value and create an ectopic splice site that is stronger than the natural splice site. (b) Hexamers
in the vicinity of the splice junctions are largely made up of ESSs. The graph represents the proportion of positions occupied either by an ESE or
ESS motif across approximately 25,000 internal exons. Each position on the graph represents the first base of a hexamer sliding across 100 bp of
the upstream and downstream introns and the first and last 50 bp of the exon. (c) Ectopic SAVs are located predominantly in the vicinity of the
splice site of the same type created, that is, the majority of ectopic splice sites created are 5’ ectopic sites and are located towards the end of
the exon close to the 5’ splice site. hSNPs that create a strong ectopic splice site computationally (’ectopic-like’ hSNPs) are distributed across the
exon in quite the opposite way, indicating the same constraints do not apply to these variants.
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of ESSs in known SAVs with a moderate to high signal to
noise ratio. Surprisingly, we also found that solely consid-
ering whether a variant causes ESE loss was a relatively
weak predictor of splice-affecting events. Although the
widely used ESEfinder matrices did not discriminate the
known SAVs from the control groups, other ESE datasets
(NI-ESE, RESCUE-ESE and Comp-ESE) showed statisti-
cally significant enrichments for ESE loss.
The study of ESR changes may not be a binary endea-
vor, as a single SNP can affect a number of putative
overlapping binding sites. We found that SAVs are
more strongly associated with the loss of large numbers
of ESEs and the gain of large numbers of ESSs. This
analysis also highlighted the neighborhood inference set
of putative ESRs (’NI-ESRs’) as providing the strongest
signal for exon skipping variants. NI-ESRs are a rela-
tively new set of predicted splice regulatory elements
and have therefore been little used in clinically asso-
ciated splicing studies to date. The neighborhood infer-
ence algorithm greatly enlarged the set of previously
known ESEs and ESSs to cover over a third of all possi-
ble hexamers, increasing the likelihood of false positives
in our ESR change analysis. We nevertheless saw
impressive separation between SAVs and hSNPs, sug-
gesting that many of these novel ESRs represent func-
tional elements. None of our test set of known exon-
skipping variants was originally identified, nor confirmed
using this dataset.
As an illustration, a published missense mutation in
exon 12 of the HEXB gene causes full exon skipping
and is responsible for chronic Sandhoff’sd i s e a s e .T h e
variant was identified experimentally and subsequently
predicted to cause the loss of two ESEfinder sites [41].
Our analysis using NI-ESRs revealed that this mutation
caused the loss of five overlapping ESEs and the creation
of two overlapping ESSs (both of which were direct con-
versions from ESEs to ESSs). Notably, this extent of NI-
ESR changes, unlike those for ESEfinder, scored as
highly discriminative forS A V sc o m p a r e dt oh S N P s .
Furthermore, we found that concurrent loss and gain
events were better predictors than single events. This
fact is illustrated by the synonymous skipping mutation
of exon 7 in SMN2 that destroys two overlapping ESE
hexamers and creates two overlapping ESS hexamers.
Functional studies of SF2/ASF and hnRNPA1 binding in
this exon proved that reduced binding of SF2/ASF [11]
and increased binding of hnRNPA1 [42] were responsi-
ble for reduced inclusion of the SMN2 exon.
Increased silencer activity is likely for many SAVs
Although the loss of ESEs is the most commonly
assigned change in published splice-associated variant
studies, increased silencer function was seen in 37% of
our known exon skipping SAVs, in which each caused
the gain of two or more ESSs. The clear enrichment for
silencer creation in SAVs and selection against silencer
acquisition in common polymorphisms suggests that
this may be a major mechanism responsible for exon
skipping. Furthermore, for mutations in which the
mechanism of action has been experimentally studied,
with the exception of SMN2,n o n ew e r es t u d i e df o rt h e
possibility of increased silencer function. The impor-
tance of exonic silencers in splicing is further high-
lighted by our results showing that SAVs that cause
increased exon-inclusion are likely to operate largely by
t h el o s so fE S S s .W ec o n c l u d e that newly created ESS
sites also facilitate formation of de novo ectopic splice
sites. The action of inhibiting a natural existing proximal
splice site, as ESS are known to do, would be similar to
those causing exon skipping when no other alternative
splice site was available.
Caveats
It is important to note that despite the strong signals we
identified, there are a number of limitations to solely
using ESR analyses in a predictive manner. For example,
even using the NI-ESR set, some SAVs were not cap-
tured with expected regulatory changes. Around 9% of
the SAVs had no relevant changes in any of the ESR
datasets, indicating that putative ESRs do not cover the
full spectrum of functional splicing regulatory elements
or these variants act through an alternative mechanism
(for example, RNA secondary structure). Furthermore,
context is very important for ESR function. This fact
was highlighted by a recent study of ‘designer’ exons
that placed different combinations of known ESEs and
ESSs within a minigene exon and found that exons with
the same proportion of enhancers and silencers exhib-
ited highly variable inclusion levels that were context
specific according to the order of regulatory elements
across the exon [43].
Exon skipping SAVs occur in weakly defined exons
Our analyses of the exonic environment suggested that
an exon-skipping outcome was not necessarily solely
dependant on the changes in splice regulatory elements,
but may also be influenced by pre-existing features of
exon definition. In this analysis SAV exons were not dis-
cernibly weaker at splice sites than other exons. How-
ever, experimental studies have indicated that weak
splice sites are a factor. For example, the 5’ splice site of
SMN2 exon 7 was reported to be suboptimal through
experimental and compensatory analyses [44]. This find-
ing was not reproducible using solely computational
scoring, highlighting the limitations of current in silico
methods in detecting subtle but potentially significant
features of exon definition.
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exon definition is influenced by ESE and ESS motif den-
sities [43]. It is revealing, therefore, that SAV exons
have significantly lower densities of ESEs and signifi-
cantly greater densities of ESSs - a clear attribute of
weak exon definition. It is currently thought that spli-
cing efficiency increases linearly as the number of
enhancer elements increases because the role of multi-
site splice-regulatory elements is to increase the prob-
ability of an interaction between the regulatory complex
and the splicing machinery [45,46]. Conversely, as the
number of silencer elements increases, splicing efficiency
decreases [43]. Indeed, we found that ESS density of
many SAV exons was more comparable to that of
introns than exons. As weakly defined exons, they
appear vulnerable to variants that further modulate the
ESE/ESS density. Illustrating the point, some exons are
vulnerable to exon skipping by numerous SAVs. Seven
SAVs occur in constitutively spliced exon 12 of the
CFTR gene [47,48], which has a low ESE density (0.280
versus 0.371) and exceptionally high ESS density (0.293
versus 0.091) compared to mean densities in HapMap
exons.
Our results also suggest that ESS elements in the
introns may play a role in the susceptibility of exons to
SAVs. However, the function of ESSs in introns is not
fully elucidated [49,50]. If ESSs in introns act mainly as
intronic splicing silencers, they may make the exon
increasingly reliant on exonic splicing enhancers. Such a
case has been demonstrated for one of the SAVs in
exon 7 of SMN1/SMN2, where removal of a flanking
intronic splicing silencer sequence compensated for the
exon skipping effect [51].
Conclusions
It is becoming increasingly clear that both missense and
synonymous mutations within exons can have devastat-
ing effects on gene function by modulating splicing. The
location of these mutations in coding sequence, as well
as the lack of a clear strategy for their identification,
means that their effects are often overlooked. As a con-
sequence, known examples are currently small in num-
ber, but are likely to be underestimated. This work
provides the first large-scale analysis of exon skipping
variants to computationally characterize their genomic
context. We identified a number of features associated
with the variants and their exonic and intronic environ-
ments that are significantly different from common spli-
cing-neutral polymorphisms. Exon skipping SAVs are
characterized by extensive loss of exonic splicing enhan-
cers and gain of splicing silencers, often in combination.
They tend to occur in regions close to splice sites and
in regions under greater non-coding evolutionary selec-
tion. They also tend to occur in exons with a fairly weak
environment for exon definition that is the likely cause
of their vulnerability to skipping events.
Our comparative approach proved robust in identify-
ing relevant features in other types of SAVs too. Var-
iants that cause increased exon inclusion are
characterized by ESS loss and, to a lesser degree, the
gain of ESEs. Variants that activate an ectopic splice site
simultaneously create large numbers of ESSs, in addition
to a strong consensus splice site, and inhibit use of the
natural splice site. These results provide greater insights
into the possible mechanism ofa c t i o no ft h e s ev a r i a n t s
and should improve strategies for identifying disease
candidates. To this end, we have developed a web-based
tool, Skippy, to score candidate human genomic variants
for features predictive of an exon-skipping outcome or
creation of an ectopic splice site.
Materials and methods
Collation of a set of known exonic variants causing exon
skipping
In total we collated a set of 87 SAVs by extracting synon-
ymous and missense variants from the Alternative Spli-
cing Mutation Database [26] (with a splicing effect score
<0), and from our own extensive literature searches. Only
single-point variants that had been experimentally veri-
fied for exon skipping were used in the reference set. We
excluded the following: nonsense variants [3] (that is,
those that create a stop codon); and variants that affect
the splice junction (that is, 3 bp or less from either splice
junction). Genomic positions for all 87 identified cases
(32 synonymous, 55 missense) were mapped back onto
the reference human genome (assembly Hg18). For the
analysis of the types of ESR changes involved in increased
exon inclusion, we used a set of 20 variants from the
Alternative Splicing Mutation Database with splicing
effect scores >0 (7 synonymous, 13 missense).
Obtaining a comparator set of putatively splicing-neutral
coding SNPs
All ‘phase II’ HapMap SNPs (release 22), termed ‘hSNPs’,
that were polymorphic in at least one individual were
downloaded from the website [27]. SNPs had to fall
within an internal coding exon (using the Ensembl
known gene set, v45.36 g) and more than 3 bp away from
a splice junction. Directionality of mutations (that is, the
derived alleles) utilized three-way human-chimp-maca-
que MulitZ alignments (hg18, panTro2, rheMac2)
obtained from the UCSC Genome Browser [52] via
Galaxy [53]. SNPs were retained only if there was a full
three-way alignment available, chimp and macaque bases
were identical, and one of the human alleles matched the
ancestral chimp-macaque base. hSNPs included within
the set of known SAVs were excluded from the compara-
tor set (rs2306159, rs4647603 and rs2295682 [54], rs688
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(rs17658212, rs4963793, rs591 and rs3818562) with
reported correlations to splicing changes (but unverified)
[57] were also excluded. A total of 15,547 hSNPs (7,922
synonymous, 7,625 missense) were obtained. Derived
allele frequencies of >5% and >10% in at least one popu-
lation were assessed. We found no appreciable difference
for any of our analyses when using SNPs with greater
derived allele frequencies. In addition to our hSNP com-
parator set, we also identified a set of 80 variants from
the literature that have been experimentally tested in
mini-gene assays and found to have no effect on exon
splicing (Additional file 2).
Changes in exonic ESRs
For our analysis, we obtained six sets of ESR sequence
prediction datasets. Three comprised sets of bioinforma-
tically defined hexamers (RESCUE-ESEs (238 ESEs) [58],
NI-ESRs (979 ESEs and 496 ESSs) [19] and Ast-ESRs
(285 undefined hexamers) [16]). PESX has bioinformati-
cally defined octamers (2,096 PESEs and 974 PESSs)
[18]). Fas-Hex2 contains experimentally defined ESS
hexamers (176 ESSs) [15]). ESEfinder has four experi-
mentally defined position weight matrices for SR protein
binding sites [59]. Composite-ESRs are a combined set
of hexamers derived from PESX, RESCUE-ESE, and Fas-
Hex2 ESS, representing 400 ESEs and 217 ESSs [60].
The effect of SNP changes on ESR predictions was cal-
culated using a sliding window that covered all hexam-
ers surrounding the variant. N-mers that did not ‘score’
as an ESE or ESS were considered splicing-neutral.
Comparisons between the wild-type sequence (or ances-
tral allele) and the variant sequence (or derived allele)
measured ESR loss (for example, an ESE to a neutral),
ESR gain (for example, neutral to an ESE) and ESR
alteration (for example, ESE to a different ESE). In the
case of NI-ESRs, PESXs and composite ESRs, ESEs and
ESSs were considered separately. For the analysis of
changes in NI-ESRs, the types of changes between
alleles were counted for all overlapping hexamers in
which the variant was present. Expected proportions for
each of the nine categories of change were calculated by
permutating every base of 4,096 hexamers to all remain-
ing bases (for example, A would be permutated to T, G
and C) to give 73,728 (4096 × 3 × 6) permutations. Base
substitution biases were taken into account by measur-
ing base substitutions in the hSNP derived allele set
(Additional file 10) and for each permutation, weighting
the ESR-change category by the proportion of base sub-
stitutions of that type.
Regulatory evolutionary constraint
An expectation-based scoring matrix measuring regula-
tory constraint in coding sequences was created by
measuring the proportion of columns fully conserved
for each of the 192 codon positions using a randomly
selected set of 62,000 internal human exons in 6,428
genes from Ensembl (v47.36i). Exons were distributed
genome-wide and had conserved counterparts in mouse,
rat and dog genomes. Scores were assigned for each
codon position by (1 - PrCODi) × 10 where PrCODi is the
proportion of columns in all the alignments that were
fully conserved for codon COD,p o s i t i o ni.S c o r e sf o r
each codon position are therefore weighted so that they
are inversely proportional to their overall conservation
level. Conservation scores, measuring non-coding con-
straint in coding sequence, were calculated for regions
surrounding variants in the hSNP and SAV sets. Ortho-
logous sequences from human, mouse, rat and dog were
extracted from 17-way MultiZ multiple alignments from
the UCSC Genome Browser [52] for 5 bp either side of
the SNP (representing all hexamers containing a SNP (a
total of 11 bp) using Galaxy python scripts [53]. Smaller
flanking regions were extracted if the variant was
located less than 5 bp from the splice junction. Only
ungapped alignments containing at least two species in
addition to human were used. The RC score surround-
ing a variant RCVar was calculated as follows:
RC
sic i
i
N
N
Var  
 
1
where N is the number of columns in the alignment, i
is the column position, Si is the conservation status of
the column (1 for conserved across the alignment, 0 if
not fully conserved) and δci is the weight of the score
depending on the codon position of the sequence of i in
human (using the 192 codon scoring matrix). Pre-com-
puted conservation scores for each base of all internal
c o d i n ge x o n si nt h eh u m a ng e n o m e( a s s e m b l yH g 1 8 )
are available as a custom wiggle track on the UCSC gen-
ome browser from [40]. For all statistical analyses, only
variants with non-overlapping regions were used to
avoid bias. To compare conservation in SAV exons and
HapMap exons, human/mouse/rat/dog multiple align-
ments were extracted across all exons represented in
both sets. We computed the proportion of non-synon-
ymous sites and proportion of columns that were fully
conserved across the alignment within each exon.
Exon-based features
All exons (and their flanking intronic sequences) con-
taining SAVs and hSNPs were extracted from the
human genome (assembly Hg18) using the Ensembl
API [61] always using the largest exon isoform (except
in the case of intron retention events). A genome-wide
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Page 16 of 23set of internal human cassette exons was downloaded
from the Hollywood exon annotation database [36].
We retained exons between 20 and 1,000 bp with
canonical GT-AG splice junctions, solely annotated as
constitutive or alternatively spliced, obtaining 105,932
exons. Of these, 98,692 were annotated as constitutive
and 7,240 were alternatively spliced. A simulated dis-
tribution of expected exon lengths for hSNPs, given a
random distribution across the genome of 1 every
thousand bases [27], was calculated for each exon
length n (going from 20 bp to 1,000 bp) using the for-
mula fr(n)=pSNP × obs(n)w h e r epSNP =0 . 0 0 1a n d
obs(n) is the observed number of exons for length n in
the set of Hollywood exons. Splice site strength at
both the 5’ and 3’ splice junctions was measured using
the MaxEntScan maximum entropy scoring program
[62] with default settings. We calculated ESR density
within an exon by scanning a window of size n
(depending on size of the ESR) across the length of the
exon, and then dividing by the number of windows
that scored as an ESE or ESS by the total number of
windows. ESEfinder densities were calculated differ-
ently due to their encoding as position weight matrices
of differing length. The density of each of the four
position weight matrices within the exon was calcu-
lated separately using the windowing method and
summed to make an overall density. We excluded the
possibility of ascertainment bias for exon features due
to expression levels by comparing 68 exons from SAV-
containing genes that contained hSNPs but not SAVs
to the rest of the hSNP exon dataset. We found no sig-
nificant differences for ESR change or exon character-
istics (such as exon length, splice site strength, ESE/
ESS density, and so on) compared to other hSNPs or
their exons.
Intron-based features
All ESE/ESS densities of intronic sequences were mea-
sured using the NI-ESR set in the same way as for
exons, on 100 bp of sequence directly flanking each side
of the exon (excluding the conserved GT-AG splice site
dinucleotides). Any exons with a flanking intron of less
than 102 bp were excluded.
Variants that activate de novo cryptic splice sites
From the DBASS3 [63] and DBASS5 [64] databases, we
obtained 54 experimentally verified examples of exonic
mutations that activate a de novo (that is, not pre-exist-
ing) ectopic 5’ or 3’ splice site and are located more
than 3 bp away from either splice junction and mapped
them back on to the human genome assembly hg18
(Additional file 9). We measured potential creation of
de novo splice sites by a variant using a metric ΔSS. ΔSS
represents the maximum change in values for either 5’
or 3’ MaxEnt splice site scores between variant and wild
type, that is, ΔSS = max(Δ5’SS|Δ3’SS). Δ5’SS =( MEvar -
MEwt)w h e r eMEvar and MEwt are the 5’ MaxEntScan
scores for the sequence including the variant and wild-
type allele, respectively. Similarly Δ3’SS is calculated in
the same way but using the 3’ MaxEntScan scoring pro-
gram. Δ5’SS and Δ3’SS were calculated for every appro-
priate sequence window (9 bp for 5’ splice sites and 23
bp for 3’ splice sites) in which a variant could play a
role, sliding the window 1 bp each time. A comparator
set of the top 54 ectopic-like hSNPs were created by
choosing those hSNPs with the greatest scores for puta-
tive ectopic splice sites created by the variant, a ΔSS ≥ 1
and no evidence of ectopic splice site creation as judged
by mRNA and EST evidence from GenBank. Interest-
ingly, prior to using the last filter, we found two of the
top 56 hSNPs have strong evidence of causing ectopic
splice site creation (rs7529443 (G->A) and rs2863095
(G->A)). This strategy, used with other evidence, can be
used to identify novel ectopic splice site creating SNPs.
To identify whether natural splice sites are predomi-
nantly made up from sequences defined as ESSs, we
used DNA sequence from 100 bp within the exon (the
first and last 50 bp in cases where the exon length >100
bp) in addition to 100 bp from the flanking upstream
and downstream introns from a subset of the constitu-
tively spliced exons with canonical GT-AG splice junc-
tions from the Hollywood database. We therefore
required that exons be at least 100 bp in length and
contain flanking introns of at least 200 bp in length (so
as not to contain mixed signal from nearby exons), leav-
ing 24,924 exons.
Statistical analysis
Unless otherwise indicated, we carried out a bootstrap
analysis to compare SAVs against the hSNP set by ran-
domly sampling sets of the same size and proportion
of synonymous and non-synonymous as the SAVs
without replacement (using the Perl module Math::
R a n d o m )f r o mt h eh S N P s1×1 0
5 times. For the analy-
sis involving ectopic SAVs, only hSNPs with a ΔSS
score of 0 were compared. The number of cases
sampled from the hSNP set for bootstrap analysis
depended on whether the parameter was variant-based
(that is, dependant on the variant, such as changes in
ESRs) or exon-based. For variant-based parameters, all
variants were used. As some SAVs or hSNPs fall
within the same exon, exon-based parameters utilized
only unique exons within the set to avoid biasing the
analysis. Z-scores were calculated as long as the distri-
bution of sampled values passed the Shapiro-Wilk test
for normality (P > 0.05) otherwise the lowest empirical
P-value was presented. P-values were derived from Z-
scores calculated using:
Woolfe et al. Genome Biology 2010, 11:R20
http://genomebiology.com/2010/11/2/R20
Page 17 of 23z
x 


where x is the feature value (or mean value) for SAVs,
μ is the mean and s is the standard deviation of a distri-
bution of feature values (or mean values) of randomly
sampled hSNPs. A more stringent a value of 0.01 was
used to determine statistical significance given the large
number of statistical comparisons carried out. Compari-
son of the proportion of SNPs showing changes in dif-
ferent motif positions within ESEfinder motifs for SAVs
and hSNPs was carried out using c
2 with Yates correc-
tion. Exon length distributions were compared using
both the sampling approach above, as well as the K-S
test as implemented in the R statistics package.
Additional file 1: Table S1 List of 87 synonymous and missense splice-
affecting genome variants (SAVs) that cause exon skipping used for
analysis in this study. The variants are derived from
[12,13,37,41,44,47,48,54-56,65-103].
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S1.pdf]
Additional file 2: Table S4 List of 80 synonymous and missense variants
that have been experimentally tested in mini-gene constructs and do
not cause changes in splicing. The variants are derived from
[74104105106].
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S2.pdf]
Additional file 3: Table S5 (a) Full results of ESR changes and bootstrap
analysis of exon skipping SAVs vs. hSNPs, (b) splice-neutral variants vs.
hSNPs, (c) SAVs that cause exon inclusion vs. hSNPs, (d) ectopic SAVs vs.
hSNPs and (e) ectopic-like hSNPs vs. hSNPs with a ΔSS of 0.
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S3.pdf]
Additional file 4: Figure S2. Proportion of exon skipping SAVs and
hSNPs that destroy an ESEfinder motif and the position in which
they occur across four binding sites Set of graphs illustrating that
exon-skipping SAVs are significantly overrepresented within certain
positions across the four ESEfinder matrices.
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S4.pdf]
Additional file 5: Methods and Results S1. Local RNA secondary
structure analysis Methods and results for an analysis on whether using
local RNA secondary structure as a filter improves our ability to
distinguish exon skipping SAVs from hSNPs. Our results suggest that
using this filter does not improve our ability to predict SAVs although a
small number of SAVs may arise from the indirect uncovering of ESS
motifs by changes in local RNA secondary structure.
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S5.pdf]
Additional file 6: Table S2 List of 20 variants that cause increased exon
inclusion. The variants are derived from [4447104107108].
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S6.pdf]
Additional file 7: Figure S3. The RC score is influenced by distance
from the splice junction but not by exon length Two plots that show
that mean RC score is negatively correlated with minimum distance from
a splice junction (top) but not correlated with exon length (bottom).
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S7.pdf]
Additional file 8: Figure S4. Distribution of exon lengths for SAV
exons versus HapMap and genome-wide exons Only distributions of
exon lengths up to 600 bp were plotted for clarity. Genome-wide exons
were divided into constitutively spliced (CE) and alternatively spliced (AS)
as defined by the Hollywood database [36]. A fifth, expected set of exons
represents a set of exon lengths we would expect given the average
distribution of hSNPs across the genome and fits the real distribution of
HapMap exons closely.
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S8.pdf]
Additional file 9: Table S3 List of 54 variants that cause de novo 5’ or 3’
ectopic splice site activation. The variants are derived from [4,37,86,109-
154].
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S9.pdf]
Additional file 10: Figure S1. Distribution of nucleotide
substitutions types in 15,547 HapMap derived alleles (’hSNPs’), 87
exon skipping SAVs (’skipping SAVs’) and 54 SAVs that create a de
novo ectopic splice site (’ectopic SAVs’) Base substitution distributions
in hSNPs were used a background nucleotide substitution rates in
calculating an expected distribution of ESE/ESS changes of the NI-ESR
hexamer set (Figure 3). Significant differences in distributions between
skipping SAVs and hSNPs (such as that seen in A->T, T->C and G->T) and
ectopic SAVs (A->T, A->C, T->A, C->G) while potentially of biological
interest, should be treated with caution due to small number of skipping
and ectopic SAVs and large discrepancy in dataset size between these
sets and HapMap SNPs.
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-2-
r20-S10.pdf]
Abbreviations
bp: base pair; ESE: exonic splicing enhancer; ESR: exonic splicing regulatory
sequence; ESS: exonic splicing silencer; EST: expressed sequence tag; hnRNP:
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